|
USRE30985E
(en)
|
1978-01-01 |
1982-06-29 |
|
Serum-free cell culture media
|
|
US4560655A
(en)
|
1982-12-16 |
1985-12-24 |
Immunex Corporation |
Serum-free cell culture medium and process for making same
|
|
US4657866A
(en)
|
1982-12-21 |
1987-04-14 |
Sudhir Kumar |
Serum-free, synthetic, completely chemically defined tissue culture media
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4767704A
(en)
|
1983-10-07 |
1988-08-30 |
Columbia University In The City Of New York |
Protein-free culture medium
|
|
GB8516415D0
(en)
|
1985-06-28 |
1985-07-31 |
Celltech Ltd |
Culture of animal cells
|
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
|
US4927762A
(en)
|
1986-04-01 |
1990-05-22 |
Cell Enterprises, Inc. |
Cell culture medium with antioxidant
|
|
AU632065B2
(en)
|
1988-09-23 |
1992-12-17 |
Novartis Vaccines And Diagnostics, Inc. |
Cell culture medium for enhanced cell growth, culture longevity and product expression
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
EP0368684B2
(en)
|
1988-11-11 |
2004-09-29 |
Medical Research Council |
Cloning immunoglobulin variable domain sequences.
|
|
US5530101A
(en)
*
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
EP1690934A3
(en)
|
1990-01-12 |
2008-07-30 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
ATE300615T1
(de)
|
1990-08-29 |
2005-08-15 |
Genpharm Int |
Transgene mäuse fähig zur produktion heterologer antikörper
|
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US5122469A
(en)
|
1990-10-03 |
1992-06-16 |
Genentech, Inc. |
Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
|
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
|
FI941572L
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
|
|
AU675929B2
(en)
|
1992-02-06 |
1997-02-27 |
Curis, Inc. |
Biosynthetic binding protein for cancer marker
|
|
EP0656064B1
(en)
|
1992-08-17 |
1997-03-05 |
Genentech, Inc. |
Bispecific immunoadhesins
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
CA2219361C
(en)
|
1995-04-27 |
2012-02-28 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
EP0823941A4
(en)
|
1995-04-28 |
2001-09-19 |
Abgenix Inc |
HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
|
|
EP0914452A2
(en)
|
1996-06-17 |
1999-05-12 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Novel ptp20, pcp-2, bdp1, clk and sirp proteins and related products and methods
|
|
US6143559A
(en)
|
1996-11-18 |
2000-11-07 |
Arch Development Corporation |
Methods for the production of chicken monoclonal antibodies
|
|
EP1500329B1
(en)
|
1996-12-03 |
2012-03-21 |
Amgen Fremont Inc. |
Human antibodies that specifically bind human TNF alpha
|
|
CA2226962A1
(en)
|
1998-02-16 |
1999-08-16 |
Marie Sarfati |
Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection
|
|
EP1048299A1
(en)
|
1999-04-28 |
2000-11-02 |
Faculteit der Geneeskunde van de Vrije Universiteit |
Method for inhibiting cell functioning for use in anti-inflammatory and anti-tumour therapies
|
|
AU1701001A
(en)
|
1999-11-30 |
2001-06-12 |
Eberhard-Karls-Universitat Tubingen Universitatsklinikum |
Antibodies against signal regulator proteins
|
|
GB9930706D0
(en)
|
1999-12-24 |
2000-02-16 |
Medical Res Council |
Composition for inhibiting macrophage activity
|
|
PT1355919E
(pt)
*
|
2000-12-12 |
2011-03-02 |
Medimmune Llc |
Moléculas com semivida longa, composições que as contêm e suas utilizações
|
|
AU2002315052A1
(en)
|
2001-05-15 |
2002-11-25 |
Emory University |
Polynucleotides and polypeptides relating to the modulation of sirp alpha-cd47
|
|
CA2513113A1
(en)
|
2003-01-23 |
2004-08-05 |
Genentech, Inc. |
Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
|
|
WO2005014653A2
(en)
|
2003-02-28 |
2005-02-17 |
Protein Design Labs, Inc. |
Humanized chicken antibodies
|
|
US20040213792A1
(en)
|
2003-04-24 |
2004-10-28 |
Clemmons David R. |
Method for inhibiting cellular activation by insulin-like growth factor-1
|
|
US20100215640A1
(en)
|
2003-04-24 |
2010-08-26 |
The University Of North Carolina At Chapel Hill |
Method for inhibiting cellular activation by insulin-like growth factor-1
|
|
US8613922B2
(en)
|
2003-04-24 |
2013-12-24 |
The University Of North Carolina At Chapel Hill |
Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
|
|
TW200902555A
(en)
|
2005-01-03 |
2009-01-16 |
Hoffmann La Roche |
Antibodies against IL-13 receptor alpha 1 and uses thereof
|
|
EP2860192B1
(en)
|
2005-10-12 |
2017-09-27 |
MorphoSys AG |
Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38
|
|
US20100239578A1
(en)
|
2007-10-11 |
2010-09-23 |
University Health Network |
Modulation of sirp-alpha - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor
|
|
AU2009205665B2
(en)
|
2008-01-15 |
2013-12-05 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for manipulating phagocytosis mediated by CD47
|
|
CA2965198C
(en)
|
2008-01-15 |
2021-02-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
Markers of acute myeloid leukemia stem cells
|
|
EP2271657B1
(en)
|
2008-03-04 |
2017-03-01 |
Crystal Bioscience Inc. |
Gel microdrop composition and method of using the same
|
|
EP2111869A1
(en)
|
2008-04-23 |
2009-10-28 |
Stichting Sanquin Bloedvoorziening |
Compositions and methods to enhance the immune system
|
|
US8592644B2
(en)
|
2009-08-13 |
2013-11-26 |
Crystal Bioscience Inc. |
Transgenic animal for production of antibodies having minimal CDRS
|
|
WO2011041453A1
(en)
|
2009-09-29 |
2011-04-07 |
The Board Of Trustees Of The Leland Stanford Junior University |
Isolation and use of melanoma cancer stem cells
|
|
EP2609194B1
(en)
|
2010-08-27 |
2019-01-16 |
University Health Network |
Methods for enriching pluripotent stem cell-derived cardiomyocyte progenitor cells and cardiomyocyte cells based on sirpa expression
|
|
CA2835222C
(en)
|
2011-05-24 |
2020-08-25 |
Crystal Bioscience Inc. |
Transgenic chicken comprising an inactivated immunoglobulin gene
|
|
WO2013056352A1
(en)
*
|
2011-10-19 |
2013-04-25 |
University Health Network |
Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
|
|
US9394372B2
(en)
|
2011-10-21 |
2016-07-19 |
Crystal Bioscience Inc. |
In vivo method for generating diversity in a protein scaffold
|
|
EP4721752A2
(en)
|
2011-12-30 |
2026-04-08 |
Cellscript, Llc |
Herstellung und verwendung von in vitro-synthetisierter ssrna zur einführung in säugetierzellen zur induktion einer biologischen oder biochemischen wirkung
|
|
CA2887706C
(en)
|
2012-11-05 |
2022-08-02 |
Regeneron Pharmaceuticals |
Genetically modified non-human animals and methods of use thereof
|
|
ES2914814T3
(es)
|
2012-12-17 |
2022-06-16 |
Pf Argentum Ip Holdings Llc |
Tratamiento de células enfermas CD47+ con fusiones SIRP Alfa-Fc
|
|
CA2900256C
(en)
|
2013-02-05 |
2023-03-21 |
Kim J. HASENKRUG |
Cd47 targeted therapies for the treatment of infectious disease
|
|
PT2970493T
(pt)
|
2013-03-15 |
2019-06-27 |
Univ Leland Stanford Junior |
Métodos para obter doses terapeuticamente eficazes de agentes anti-cd47
|
|
ES2898627T3
(es)
|
2013-04-29 |
2022-03-08 |
Univ Leland Stanford Junior |
Uso de agentes anti-CD47 para mejorar la inmunización
|
|
ES2765483T3
(es)
|
2013-09-18 |
2020-06-09 |
Univ Leland Stanford Junior |
Modulación de las vías de eferocitosis para el tratamiento de una enfermedad aterosclerótica
|
|
ES3012974T3
(en)
|
2014-01-08 |
2025-04-10 |
Univ Leland Stanford Junior |
Targeted therapy for lung cancer
|
|
AU2015229448B2
(en)
|
2014-03-11 |
2020-09-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Anti SIRP-alpha antibodies and Bi-specific Macrophage Enhancing antibodies
|
|
TWI759810B
(zh)
|
2014-08-08 |
2022-04-01 |
美商Ａｌｘ腫瘤技術股份有限公司 |
信號調節蛋白α(signal-regulatory proteinα, SIRP-α)變體構築物及其用途
|
|
HUE046661T2
(hu)
|
2014-08-15 |
2020-03-30 |
Merck Patent Gmbh |
SIRP-alfa immunglobulin fúziós proteinek
|
|
FI3656869T4
(fi)
|
2014-08-26 |
2025-06-04 |
Univ Leland Stanford Junior |
Kantasolujen siirrostaminen kantasoluihin kohdentuvan aineen ja immunoregulatorista signaalia moduloivan aineen yhdistelmän kanssa
|
|
EP3209769B1
(en)
|
2014-10-24 |
2020-08-05 |
The Board of Trustees of the Leland Stanford Junior University |
Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
|
|
EP3012271A1
(en)
|
2014-10-24 |
2016-04-27 |
Effimune |
Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases
|
|
EP3247464B1
(en)
|
2015-01-21 |
2019-09-18 |
The Board of Trustees of the Leland Stanford Junior University |
Use of tlr agonist and anti-cd47 agent to enhance phagocytosis of cancer cells
|
|
US10618976B2
(en)
|
2015-06-16 |
2020-04-14 |
The Board Of Trustees Of The Leland Stanford Junior University |
SIRP-α agonist antibody
|
|
RU2766690C2
(ru)
|
2015-07-28 |
2022-03-15 |
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания |
Модифицированные моноциты/макрофаги, экспрессирующие химерные антигенные рецепторы, и их применения
|
|
EP3341015B2
(en)
|
2015-08-26 |
2023-12-27 |
The Board of Trustees of the Leland Stanford Junior University |
Enhanced depletion of targeted cells with cd47 blockade and an immune costimulatory agonist
|
|
JP7078533B2
(ja)
|
2015-10-21 |
2022-05-31 |
オーエスイー イムノセラピューティクス |
炎症促進性細胞へのマクロファージ分極を改変して癌を治療するための抗ＳＩＲＰａ化合物
|
|
US10946042B2
(en)
|
2015-12-01 |
2021-03-16 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for selective phagocytosis of human cancer cells
|
|
AU2016365829B2
(en)
|
2015-12-11 |
2020-02-06 |
The Board Of Trustees Of The Leland Stanford Junior University |
Treatment of cancer with dual targeting of CD47 and EGFR
|
|
EP3442541B1
(en)
|
2016-04-10 |
2021-11-17 |
Georgia State University Research Foundation, Inc. |
Composition for use in treating cancer
|
|
RS66062B1
(sr)
|
2016-04-14 |
2024-11-29 |
Ose Immunotherapeutics |
Nova anti-sirpa antitela i njihove terapijske primene
|
|
SG11201808465UA
(en)
*
|
2016-04-14 |
2018-10-30 |
Ose Immunotherapeutics |
NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS
|
|
US20190153095A1
(en)
|
2016-07-05 |
2019-05-23 |
National University Corporation Kobe University |
Antitumor Agent
|
|
KR102878970B1
(ko)
|
2016-08-03 |
2025-10-30 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
항-SIRPalpha 항체 요법의 대식세포 증진 효능에서 Fc 수용체 참여의 붕괴
|
|
JOP20190009A1
(ar)
|
2016-09-21 |
2019-01-27 |
Alx Oncology Inc |
أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
|
|
CN118027200A
(zh)
|
2016-12-09 |
2024-05-14 |
艾利妥 |
抗SIRPα抗体及其使用方法
|
|
JP7321934B2
(ja)
|
2017-01-30 |
2023-08-07 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
幹細胞移植のための非遺伝毒性移植前処置レジメン
|
|
CN118267470A
(zh)
|
2017-04-13 |
2024-07-02 |
赛罗帕私人有限公司 |
抗SIRPα抗体
|
|
CN118271443A
(zh)
|
2017-05-16 |
2024-07-02 |
拜奥迪斯私人有限公司 |
抗SIRPα抗体
|
|
WO2019023347A1
(en)
|
2017-07-26 |
2019-01-31 |
Forty Seven, Inc. |
ANTI-SIRP-ALPHA ANTIBODIES AND ASSOCIATED METHODS
|
|
MX2020009774A
(es)
|
2018-03-21 |
2020-10-08 |
Alx Oncology Inc |
Anticuerpos contra proteína alfa reguladora de señal y métodos de uso.
|
|
EP3802602A1
(en)
|
2018-05-25 |
2021-04-14 |
Alector LLC |
Anti-sirpa antibodies and methods of use thereof
|
|
KR20250079073A
(ko)
|
2018-07-10 |
2025-06-04 |
고쿠리츠다이가쿠호진 고베다이가쿠 |
항 SIRPα 항체
|
|
US11591390B2
(en)
|
2018-09-27 |
2023-02-28 |
Celgene Corporation |
SIRP-α binding proteins and methods of use thereof
|
|
EP3880239A4
(en)
|
2018-11-14 |
2022-11-23 |
Arch Oncology, Inc. |
THERAPEUTIC SIRPalpha ANTIBODIES
|
|
CA3118966A1
(en)
|
2018-11-15 |
2020-05-22 |
Byondis B.V. |
Humanized anti-sirpa antibodies
|